(Q35692950)

9 August 2017

1 reference

title

Imaging Alzheimer's disease: clinical applications (English)

1 reference

9 August 2017

0 references

Satoshi Minoshima

1

1 reference

9 August 2017

1 November 2003

1 reference

Neuroimaging clinics of North America

9 August 2017

1 reference

9 August 2017

13

1 reference

9 August 2017

4

1 reference

9 August 2017

769-780

1 reference

Dementia: case ascertainment in a community survey

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Prevalence of Alzheimer's disease and other dementias in an elderly urban population: Relationship with age, sex, and education

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Measurements of regional cerebral blood flow and metabolism in psychopathological states

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Alzheimer's disease: focal cortical changes shown by positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Imaging local brain function with emission computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Cortical abnormalities in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Positron emission tomography with [18F]fluorodeoxyglucose differentiates normal pressure hydrocephalus from Alzheimer-type dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Posterior cingulate cortex in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Distribution of cerebral degeneration in Alzheimer's disease. A clinico-pathological study

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Selective loss of central cholinergic neurons in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Changes in brain cholinesterases in senile dementia of Alzheimer type.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

The cholinergic hypothesis of geriatric memory dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Autoradiographic evidence that (R)-3-quinuclidinyl (S)-4-fluoromethylbenzilate ((R,S)-FMeQNB) displays in vivo selectivity for the muscarinic m2 subtype.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

In vivo competition studies of Z-(-,-)-[125I]IQNP against 3-quinuclidinyl 2-(5-bromothienyl)-2-thienylglycolate (BrQNT) demonstrating in vivo m2 muscarinic subtype selectivity for BrQNT.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Iodine-123 labelled Z-(R,R)-IQNP: a potential radioligand for visualization of M(1 )and M(2) muscarinic acetylcholine receptors in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Muscarinic acetylcholine receptors in Alzheimer's disease. In vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

In vivo measurement of acetylcholinesterase activity in the brain with a radioactive acetylcholine analog

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[11C]methylpiperdin-4-yl propionate ([11C]PMP).

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

In-vivo measurement of activated microglia in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[(11)C]methylpiperidin-4-yl acetate without arterial blood sampling: methodology of shape analysis and its diagnostic power for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Mapping histology to metabolism: coregistration of stained whole-brain sections to premortem PET in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Neuropathological stageing of Alzheimer-related changes

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

The differentiation of depression from dementia by temporal lobe magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

MRI of entorhinal cortex in mild Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

The cortical topography of temporal lobe hypometabolism in early Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Anatomical mapping of functional activation in stereotactic coordinate space.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

A voxel-based analysis of cerebral perfusion in dementia and depression of old age.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Posterior cortical atrophy in Alzheimer's disease: analysis of a new case and re-evaluation of a historical report.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Presenile dementia with Alzheimer-, Pick- and Lewy-body changes

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Neuroleptic sensitivity in patients with senile dementia of Lewy body type

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Cognitive decline is faster in Lewy body variant than in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

[18F]FDG-PET study in dementia with Lewy bodies and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

The validity of 3 clinical diagnostic criteria for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Early detection of Alzheimer's disease: a statistical approach using positron emission tomographic data

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Sensitivity and specificity of positron emission tomography and magnetic resonance imaging studies in Alzheimer's disease and multi-infarct dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Subgroups in dementia of the Alzheimer type identified using positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Impairment of neocortical metabolism predicts progression in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Quantitative topographical EEG compared to FDG PET for classification of vascular and degenerative dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2803%2900099-6

7 January 2021

10.1016/S1052-5149(03)00099-6

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

15024960